NewAmsterdam Pharma N.V. (NAMSW)

NasdaqGM: NAMSW · 即時價格 · USD

16.51

+0.00 (0.00%)

收盤價： Aug 20, 2026, 1:30 PM

股價、關鍵數字和最新消息，都在這一頁。

0.00% (1D)

無可用資料

買價	n/a
市值	n/a
營收 (ttm)	7.12M
淨利（ttm）	-259.5M
	0.11
	n/a
	n/a
	n/a
P/B (ttm)	3.08
P/S (ttm)	n/a
財報日期	n/a

賣價	n/a
成交量	0
20 日平均成交量	1,195
開盤價	24.41
前收盤價	16.51
當日區間	16.51 - 16.51
52 週範圍	12.69 - 30.45
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 NAMSW

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is ...

[閱讀更多]

產業

類股

IPO 日期 Feb 10, 2021

員工 100

證券交易所 NasdaqGM

股票代號 NAMSW

網站 https://www.newamsterdampharma.com

完整的公司簡介

財務表現

NewAmsterdam Pharma 在 2025 年的營收為 22.5M，較前一年的 45.56M 減少 -50.61%。淨利為 -203.82M，較前期減少 -15.64%。

財務報表

新聞動態

3 週前 · MarketBeat

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma (NASDAQ:NAMS) used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial p...

3 週前 · Zacks

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for ...

2 月前 · Simply Wall St.

A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness

Recent trading context for NewAmsterdam Pharma (NasdaqGM:NAMS) NewAmsterdam Pharma (NasdaqGM:NAMS) has drawn fresh attention after recent trading, with the stock closing at US$29.33. The move comes al...

3 月前 · Motley Fool

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.

3 月前 · Motley Fool

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.

第 1 頁，共 2 頁

NewAmsterdam Pharma N.V. (NAMSW)

關於 NAMSW

財務表現

財報驚奇

價格為何變動